A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the response rate, duration of
response,progression-free survival and overall survival of subjects with advanced melanoma
treated with TH-302.